At a glance
ClinicalIndex Comparison RecordN/ACompleted· 9 enrolled
Drug / intervention
QBX258drug
Likely dose
QBX258 3mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)
In Brief
A clinical study evaluating QBX258 for Breast Cancer and Upper Extremity Lymphedema. Completed, enrolled 9 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the efficacy of QBX258, a compound developed by Novartis Corporation composed of two antibodies, in reducing arm volume excess in women with stage I-II breast cancer related lymphedema.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Upper Extremity Lymphedema
CountriesUnited States
CollaboratorsNovartis
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJul 2015
First PostedJul 2015
Primary CompletionMay 2018
TodayJul 2026
First PostedJul 10, 2015
Enrollment StartJul 1, 2015
Primary CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.0 years ago
Interventions
QBX258drug
Once patients are registered for the trial, they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.